Drug Profile
SR 67029i
Alternative Names: SB 248424Latest Information Update: 21 Jan 2008
Price :
$50
*
At a glance
- Originator Unknown
- Developer Genzyme Oncology; GlaxoSmithKline
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 05 Jan 2005 No development reported - Preclinical for Hyperlipidaemia in Switzerland (unspecified route)
- 30 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation and is now called Genzyme Oncology
- 08 Aug 2002 Preclinical trials in Hyperlipidaemia in Switzerland (unspecified route)